This module uses fundamental data of Adaptimmune Therapeutics to approximate its Piotroski F score. Adaptimmune Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Adaptimmune Therapeutics Plc. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Adaptimmune Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Adaptimmune Therapeutics Altman Z Score, Adaptimmune Therapeutics Correlation, Adaptimmune Therapeutics Valuation, as well as analyze Adaptimmune Therapeutics Alpha and Beta and Adaptimmune Therapeutics Hype Analysis.
At this time, it appears that Adaptimmune Therapeutics' Piotroski F Score is Healthy. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
Adaptimmune Therapeutics Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Adaptimmune Therapeutics is to make sure Adaptimmune is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Adaptimmune Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Adaptimmune Therapeutics' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Adaptimmune Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Adaptimmune Therapeutics in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
0.19
At this time, Adaptimmune Therapeutics' Book Value Per Share is relatively stable compared to the past year.
Adaptimmune Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adaptimmune Therapeutics from analyzing Adaptimmune Therapeutics' financial statements. These drivers represent accounts that assess Adaptimmune Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adaptimmune Therapeutics' important valuation drivers and their relationship over time.
About Adaptimmune Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adaptimmune Therapeutics Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptimmune Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptimmune Therapeutics Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.